Indicators on Clinical trial recruitment for ABBV-744 study You Should Know
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will receive treatment until finally illness progression or even the individuals are unable to tolerate the study drugs.Ubiquitin-relevant proteins that control The soundness of vital Tremendous enhancer-medi